To further understand the molecular mechanisms involved in the effect of anti-PD-1 therapy on lung cancer cells, we propose here an original study aiming at defining whether an epitranscriptomic reprogramming of miRNAs (i.e., their adenosine, cytosine, and guanosine methylation, here) in lung cancer cells could account for the escape of the anti-PD-1 therapy. This evidence concerns the gene PDCD1 and lung cancer.